Navigation Links
ReBuilder Medical Technologies, Inc. Seeks a Bigger and More Credible Equity Market - 'NASDAQ, here we come!'
Date:4/7/2008

CHARLES TOWN, W.Va., April 7, 2008 /PRNewswire-FirstCall/ -- ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM), President/CEO, David B. Phillips, Ph.D, today announced that the corporation is ready to grow into one of the larger, more efficient, and transparent public equity markets.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )

"We have been a publicly held company for a year and have experienced the limitations of being listed only on the Pink Sheets with a large number of shares and a low price per share" said Dr. Phillips. "We have maintained a fully reporting status on Pink Sheets, and are prepared to meet the requirements that the NASDAQ and other markets require. Recent publicity surrounding these small equity markets indicates that without changing the percentage of ownership for our shareholders, we can add value by ensuring our price per share is in line with the larger markets. We do not anticipate offering any new equities, nor do we anticipate using any debt instruments. We are comfortable being a cash company with no receivables and no debt."

"Our next focus will be to evaluate the equity structure of our company to enable us to reach bigger equity markets that can better reflect our credibility. We are reviewing the relevant data and will keep our current investors apprised of our progress," states Dr. Phillips.

For more information visit: http://www.rebuildermedical.com and http://www.molluscum.com.

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.


'/>"/>
SOURCE ReBuilder Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Reports 1st Quarter 2008 Sales Increase of Over 88%
2. ReBuilder Medical Technologies, Inc. Announces Top Sales Month - $410,000
3. ReBuilder Medical Technologies, Inc. Announces Best Sales Day in 5 Years
4. ReBuilder Medical Technologies, Inc. Announces Revolutionary Electronic Zapper Said to Destroy Molluscum Contagiosum Pathogen
5. ReBuilder Medical Technologies, Inc. Announces 2007 Sales Nearly Doubled Sales in 2006
6. ReBuilder Medical Technologies, Inc. Expands R&D of New Products
7. ReBuilder Medical Technologies, Inc. Announces Televised Broadcast
8. ReBuilder Medical Technologies, Inc. 4th Quarter Sales Increase 100% Exceeding Projections
9. ReBuilder Medical Technologies, Inc. Reports Doubled Profits for October
10. ReBuilder Medical Technologies, Inc. Announces Record Sales Month
11. ReBuilder Medical Technologies, Inc. Celebrates Five Years and 50,000th Shipment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen ... LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug & ... is also a Lead Sponsor of the conference. , Cohen, who chairs the firm’s ...
(Date:12/2/2016)... ... 2016 , ... For over twenty-four years, Doctors on Liens has published a directory ... high quality medical care. When the company started in 1997, the directory was a ... day and the now ten-page directory features a vast array of medical specialists ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... announces the launch of its 60-day free trial program for all of the ... make the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers ...
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. ... Mediaplanet, Dr. Murthy explains how he was inspired to practice medicine at an early ... medicine is about more than making diagnoses and prescribing medicine,” he states. “It is ...
(Date:12/2/2016)... CA (PRWEB) , ... December 02, 2016 , ... ... surgeon in Beverly Hills, California, will be included in the 2016 “Guide to ... to exceptional professionals based on the amalgamation of their education, experience, and professional ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016 ... to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... of ropeginterferon alfa-2b versus HU AOP will ... trial CONTINUATION-PV to obtain European marketing authorization in the coming ... to the FDA as it seeks approval for commercialization in ...
(Date:12/4/2016)... NEW ORLEANS , Dec. 2, 2016  Former Attorney ... Foti, Jr., Esq. , a partner at the law firm ... has commenced an investigation into Lannett Company, Inc. (NYSE: ... Bloomberg published an article titled "U.S. Charges in ... an "antitrust investigation by the Justice Department, begun about two ...
(Date:12/4/2016)... Dec. 3, 2016  Results from the Phase II ... anti-P-selectin antibody, reduced the median annual rate of sickle ... (1.63 vs 2.98, p=0.010) in patients with or without ... data are being featured in the official press briefing ... (ASH) Annual Meeting and presented during the Plenary Scientific ...
Breaking Medicine Technology: